Accelerate Diagnostics (STU:1A80) Change In Receivables : €0.14 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Change In Receivables?

Accelerate Diagnostics's change in receivables for the quarter that ended in Mar. 2024 was €0.36 Mil. It means Accelerate Diagnostics's Accounts Receivable declined by €0.36 Mil from Dec. 2023 to Mar. 2024 .

Accelerate Diagnostics's change in receivables for the fiscal year that ended in Dec. 2023 was €-0.22 Mil. It means Accelerate Diagnostics's Accounts Receivable increased by €0.22 Mil from Dec. 2022 to Dec. 2023 .

Accelerate Diagnostics's Accounts Receivable for the quarter that ended in Mar. 2024 was €2.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Accelerate Diagnostics's Days Sales Outstanding for the three months ended in Mar. 2024 was 69.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Accelerate Diagnostics's liquidation value for the three months ended in Mar. 2024 was €-34.47 Mil.

Accelerate Diagnostics Change In Receivables Historical Data

The historical data trend for Accelerate Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Change In Receivables Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.23

1.31

-0.79

-0.09

-0.22

Accelerate Diagnostics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.01	0.08	-0.30	0.02	0.36

Accelerate Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.14 Mil.

Accelerate Diagnostics (STU:1A80) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accelerate Diagnostics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.04	/	2.687	*	91
=	69.28

2. In Ben Graham's calculation of liquidation value, Accelerate Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Accelerate Diagnostics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	14.491	-	51.982	+	0.75 * 2.04	+	0.5 * 2.989
=	-34.47

Accelerate Diagnostics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (STU:1A80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AXDX:USA AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines